R2D2 trial: deprescribing anticholinergics may shield aging brains

NCT ID NCT04270474

Completed Prevention Sponsor: Indiana University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests whether a pharmacist-led program to stop certain medications (anticholinergics) can lower dementia risk in older adults. 344 participants aged 65+ who take these drugs will be followed for 2 years, comparing cognitive changes and quality of life between those who deprescribe and those who continue usual care. The goal is to see if reducing these medications improves thinking and memory.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: deprescribing of anticholinergic medications
What this could lead to: If successful, this could show that stopping certain medications reduces dementia risk and improves cognitive function in older adults.
What could go wrong: This is a relatively small, early-stage trial (344 participants) focused on a specific medication class. Results may not apply to all older adults, and deprescribing may not significantly impact cognition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE, LATE ONSET are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Alzheimer disease 2 dementia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE, LATE ONSET DEMENTIA

Contacts and locations

Locations

Community Health Network Foundation, Inc.

Indianapolis, Indiana, 46256, United States
Indiana University Health

Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.